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Abstract: A right heart metastasis of a small-cell lung cancer was
found on the whole-body 18F-fluoro-deoxy-glucose positron emis-
sion tomography/computed tomography (18F-FDG-PET/CT) of a
69-year-old smoker investigated for a right pulmonary mass discov-
ered on chest radiography after a fracture of the right humerus. The
PET scan showed an increased FDG uptake by the mass in the right
lung and an intense, atypical focal activity of the right ventricle
strongly suggestive of a neoplastic process. CT-guided lung biopsy
revealed a small-cell lung cancer and myocardial biopsy confirmed
the presence of a cardiac metastasis. The patient was treated with six
cycles of chemotherapy followed by radiation therapy, which in-
cluded the heart lesion. At follow-up PET/CT 2 months after the end
of treatment, the abnormal cardiac uptake had disappeared, whereas
increased FDG uptake persisted in the pulmonary residual mass.
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Cardiac metastases are very rare, a 2.3% prevalence hasbeen found among 11,432 consecutive autopsies.1 They
are, however, still more frequent than primary cardiac tu-
mors. More than one third (36%) of cardiac metastases
originate from lung cancer, non solid primary malignancies
such as leukemia, lymphoma, and Kaposi sarcoma account
for 20%; breast carcinoma for 7%; and carcinoma of the
esophagus for 6%.2 Seventy-five percent of primary cardiac
tumors are benign, primarily atrial myxomas, the remaining
25% are malignant, most frequently sarcomas.3 Until now,
only tumors of the central nervous system have not been
demonstrated to develop cardiac metastases.4Heart is an un-
usual site for metastases because of the relative avascularity
of the endocardium, the vigorous kneading action of the
myocardium, the rapid blood flow through the heart and the
paucity of lymphatic communications between the heart and
surrounding tissues.5
CASE REPORT
Chest radiography in a 69-year-old male smoker,
treated for type II diabetes, hypertension, hyperlipidemia, and
hypothyroidism was performed because of persistent right
thoracic pain after a fracture of the right humerus. Fracture
was secondary to trauma and it was treated conservatively
without further investigation (no tissue material was obtained
from it). It showed a mass in the right upper lung suspect of
malignancy. Initial workup included an enhanced computed
tomography (CT) which confirmed the tumor (10  6.5 cm)
in the right upper lobe associated to lytic lesions of the 3rd
and 4th right ribs. Whole-body 18F- fluoro-deoxy-glucose
positron emission tomography (18F-FDG PET)/CT demon-
strated an increased uptake in the mass extending into the
lateral and posterior parts of the 2nd to the 5th rib. It also
showed activity in enlarged right inferior paratracheal and
right hilar lymph nodes. Intense focal activity in the right
ventricle corresponding in retrospect to a slightly hypodense
area on noncontrast enhanced CT was strongly suggestive of
malignancy (Figures 1A, 2A). A CT-guided biopsy of the lung
mass revealed the presence of small-cell lung cancer. Right
heart catheterization with myocardial biopsy confirmed a
cardiac metastasis (Figures 3, 4). The patient reported no
cardiac symptoms, there were no abnormalities on physical
examination. Electrocardiograph demonstrated a right bun-
dle branch block, stable for the last 5 years at least, when
compared with previous recordings, and chronic atrial
fibrillation.
The patient was treated by chemotherapy which con-
sisted in a combine treatment of 6 cycles of Carboplatin (area
under curve  5560 mg iv) and Etoposide (100 mg/m2, 210
mg iv) followed by radiation therapy with a total dose of 60
Gy to the lung mass including the mediastinal lymph nodes
and the cardiac metastasis.
Two months after the end of treatment, a follow-up
18F-FDG PET/CT revealed no residual 18FDG uptake at the site
of the cardiac metastasis (Figures 1B, 2B). The pulmonary mass,
had slightly decreased in size (8.5 5cm) but showed persistent
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18F-FDG uptake. Mediastinal lymph nodes were normal in size
without any increased 18F-FDG uptake. Image of rib invasion
was unchanged and electrocardiograph remained unmodified.
Three months after the end of radiotherapy, the patient
underwent palliative chemotherapy because of disease pro-
gression, complicated by an episode of acute bilateral pul-
monary embolism. He died 20 months after the diagnosis of
small-cell lung cancer.
DISCUSSION
Metastatic cells can reach the heart by different path-
ways: lymphatic or hematogenous spread; direct extension,
usually from mediastinal tumors; or intracavitary extension
from the inferior vena cava, through pulmonary veins,6 from
abdominal tumors, such as renal cell carcinomas, leiomyoma
of the uterus, pheochromocytoma and hepatocellular carcino-
mas.4,7 In descending order of frequency, pericardium, myo-
cardium, and endocardium are compromised. Pericardial or
myocardial involvement depends on the preferential meta-
static pathway, lymphatic or hematogenous, of the primary
tumor.4 Although cardiac metastases are usually small and
multiple, single large tumors are also observed. Like in this
patient, the right side of the heart is most commonly affected,
but the left side may also be involved.4 Metastatic lesions are
preferentially located in the pericardium, whereas primary
cardiac neoplasms arise most frequently from the endocar-
dium, followed by the cardiac muscle, and finally, the peri-
cardium.7
Intracardiac metastasis are frequently asymptomatic
even though they can cause symptoms that reflect the site and
extension of the mass. There can be pericardial effusion due
to pericardial involvement, atrial or ventricular arrhythmias,
conduction abnormalities such as atrioventricular block by
invasion of the cardiac conduction system or of the providing
coronary artery, anginal pain and myocardial infarction oc-
casioned by coronary embolism, compression or invasion of
the coronary arteries4,8. Intracavitary metastases of the right
FIGURE 1. Maximal intensity projection image (MIP) of: A,
pretherapeutic positron emission tomography/computed
tomography (PET/CT) showing increased uptake of 18F-flu-
orodeoxyglucose (FDG) in the large lung tumor of the upper
right lobe (*) with central necrosis (standardized uptake
value [SUVmax] from 15 to 25 g/ml). Note also a high up-
take in the right hilar and mediastinal lymph nodes. Focal
increased uptake is visualized in the right ventricle corre-
sponding to the heart metastasis confirmed later (arrow). B,
Follow-up PET/CT several weeks after chemo-radiotherapy.
The cardiac lesion (arrow) as well as mediastinal and hilar
lymph nodes show no longer increased tracer uptake while
the residual lung tumor still accumulates 18F-FDG (SUVmax
20 g/ml).
FIGURE 2. A, Transaxial images
of the pretherapeutic computed
tomography (CT), positron emis-
sion tomography (PET)/CT fusion
and PET showing the cardiac me-
tastasis appearing as a focal 18F-
FDG uptake in the right ventricle
(SUVmax 13 g/ml) and a hypo-
dense area on native CT (arrow).
B, On the posttherapy PET/CT the
cardiac metastasis is no longer
visible.
FIGURE 3. Ventriculography performed during right ventri-
cle catheterization showing an apical mass molded by the
contrast agent (arrow).
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ventricle may lead to pulmonary embolism, those of the left
ventricle to systemic embolism. Sudden death due to fatal
arrhythmia in relation with tumor infiltration of the conduct-
ing fibers has been described in a case of cardiac metastasis
of tongue cancer.9
Visualization of right heart masses by CT may be
difficult, even with contrast enhancement because routine
chest CT is typically performed with a single-infusion con-
trast bolus protocol. Cardiac-gated CT requiring a dual-phase
infusion protocol using a second, more diluted bolus would
be needed to better depict right-ventricle cardiac metastasis.10
Although CT has better spatial and temporal resolution,
magnetic resonance imaging is the preferred imaging modal-
ity because of overall better soft tissue contrast10 and the
ability to characterize tumor infiltration and tumor type.7
Cardiac gadolinium-enhanced magnetic resonance imaging is
currently the reference standard for noninvasive imaging of
cardiac masses. Along with cine and T2-weigthed images, the
standard perfusion and myocardial delayed-enhancement se-
quences are helpful in characterizing tumor vascularity and
allow assessment of wall motion, inflow and outflow obstruc-
tion, and valve regurgitation.7
Cardiac uptake of 18FDG is variable not only from one
patient to another, but even in the same patient imaged on
different occasions. Uptake variations are found in both, the
right and left ventricle. It ranges from no discernible activity
to intense accumulation depending on substrate availability
and need.11 During fasting state, myocardium depends on
fatty acids to produce energy12 and not much myocardial
uptake is expected but nevertheless possible. Myocardial
uptake is enhanced in the presence of high glucose levels,
therefore activity is marked in the postprandial state.12 De-
tection of cardiac lesions is difficult because they can be
masked by diffusely high normal glucose uptake or by het-
erogeneous accumulation of the glucose analogue that usually
does not correspond to any anatomic substrate.
In the initial stage of the disease,9 cardiac metastasis
usually stays asymptomatic mostly due to their small size4
and therefore remain undetected. Once they become symp-
tomatic, patients are usually already in an advanced stage of
their disease. Careful checking for abnormal cardiac uptake
of 18F-FDG allows early detection of cardiac metastases so
that they can be included in treatment planning to avoid
progression to irreversible and severe cardiac illness and even
fatal outcome.
CONCLUSION
The heart, except for pericardial involvement, is an
under-recognized site of metastatic disease in patients with
cancer. In FDG-PET scans cardiac walls should be examined
carefully to recognize any abnormal uptake. Special attention
is needed in case of very intense or heterogeneous myocardial
uptake in order not to miss tumor involvement of the heart.
Despite the fact that routine CT is not the standard method for
the detection of heart metastases, radiologists should be
aware of this possibility in searching fine anatomic alterations
or faint contrast changes within the myocardium. Combined
PET/CT performed during initial staging or restaging of
neoplastic diseases increases the chance of finding cardiac
metastases at an early stage and therefore allowing adequate
treatment before they become symptomatic.
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